Pre-market gainers: Zogenix, Inc. (NASDAQ:ZGNX), Novavax (NASDAQ:NVAX), NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), Repligen Corporation (NASDAQ:RGEN)

Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that the U.S. District Court in Massachusetts entered an order, preventing the implementation of the Commonwealth’s ban of Zohydro™ ER on Constitutional grounds. This order will become effective on April 22, 2014. Zogenix, Inc. (NASDAQ:ZGNX) stock opened today at $2.57 and is currently trading at $2.61. The stock showed a positive weekly performance of -9.65%.

Novavax, Inc. (NASDAQ:NVAX) is a $805 million biotech that develops vaccines for a number of diseases. The stock is currently in a pullback, but this is not surprising because it is happening everywhere in the healthcare sector. But even so, the pullback in Novavax only creates a buying opportunity for long-term outlook investors. Novavax, Inc. (NASDAQ:NVAX) stock opened at $3.74, in current trading session and currently is at $3.86, by gaining 4.60%.The 52 week range of $1.68-$6.95. Company’s market capitalization is $806.96 million.

NPS Pharmaceuticals, Inc.(NASDAQ:NPSP) with product pipeline which is rich in treating rare human diseases, is clocking time on the stock market as it waits for its new breed of drugs, as these in various pre-market stages of pre-clinical to clinical stage of testing and study. From the prior success of three key products, this Bedminister-based biopharmaceutical has definitely left its pioneering footprint. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) stock is currently trading at $25.20.The EPS of the stock is -0.15. Company’s market capitalization is $2.62 billion.

Repligen Corp. (NASDAQ:RGEN)‘s stock had its “buy” rating restated by research analysts at Jefferies Group in a report released on Tuesday, Analyst Ratings Network reports. They currently have a $17.00 price objective on the stock. Jefferies Group’s target price suggests a potential upside of 24.36% from the company’s current price. Repligen Corporation (NASDAQ:RGEN) stock opened the session at $15.61, and now is at $14.90. The 52 week range of the RGEN stock remained $7.37-$17.26 and the day range was $14.91-$15.61.